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Abstract
Background: Fabry disease is a lysosomal X-linked enzyme deficiency of α-galactosidase A
associated with an increased mortality and morbidity due to renal failure, cardiac disease and early
onset stroke.
Methods: We examined the functional blood flow response of the brain after visual stimulation
(reversing checkerboard pattern), and cerebral vasoreactivity following acetazolamide (15 mg/kg)
with [15O]H2O and positron emission tomography (PET) in Fabry disease. Twenty-six hemizygous
patients (age range 19–47 years) were enrolled in a randomized double-blind placebo-controlled
6-month trial of enzyme replacement therapy administered by intravenous infusion every two
weeks. Regional cerebral blood flow (rCBF) was measured with PET at the beginning and end of
the trial.
Results: Fabry patients had a significantly greater increase in rCBF following visual stimulation and
acetazolamide challenge compared to controls. Visual reactivity was normal. The time for recovery
of the cerebral vasculature following acetazolamide was prolonged in Fabry patients compared to
controls. The abnormal rCBF response induced by visual stimulation and acetazolamide decreased
significantly following enzyme replacement therapy, as did the prolonged recovery of the cerebral
vasculature.
Conclusions: Enzyme replacement therapy reverses the exaggerated cerebrovascular response in
Fabry disease.
Background
Fabry disease is an X-linked disorder resulting in reduced
activity of the lysosomal enzyme α-galactosidase A [1,2].
This results in the systemic accumulation of D-galatosyl
conjugates, particularly globotriosylceramide (Gb3) [3,4].
Although the disorder is heterogeneous, patients suffer re-
nal, cardiovascular and cerebrovascular complications
[4]. Enzyme replacement therapy has recently shown to
have an effect on resting cerebral blood flow abnormali-
ties and on other organ systems functions [5,6]. In the cer-
ebrovascular system there is an increased incidence of
stroke together with vessel ectasia [7]. This may be related
to the progressive accumulation of storage material in the
cerebral vessel or possibly, may be due to an abnormality
of vessel function [8,9]. The cerebrovascular complica-
tions are distributed predominantly in the posterior circu-
lation with a progressive increase over time in the
posterior distribution of small vessel disease as found on
T2-weighted images or fluid attenuated inversion recovery
(FLAIR) MR [7,10,11]. It likely that such high signal le-
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ease, however, there are no neuropathological-
radiological correlative studies confirming this assump-
tion. Since ischemic brain lesions are irreversible, and ac-
cumulate over years, demonstrating a reduction in
incidence is likely to require prolonged therapy in a rela-
tively large cohort of patients following this disease end-
point. Previously, in Fabry disease, we have reported rest-
ing cerebral hyper-perfusion in a predominantly vertebro-
basilar distribution together with abnormalities of vascu-
lar nitrotyrosine staining. This was reversed by enzyme re-
placement therapy [5,10]. The current study examines the
cerebrovascular system in Fabry disease in response to
functional and pharmacological activation.
We hypothesized that the cerebral vasculopathy of Fabry
disease is associated with abnormal cerebrovascular re-
sponses, and furthermore, that these would normalize
with repeated intra-vascular infusion of α-galactosidase A
[5,6]. We compared the functional cerebrovascular re-
sponses in Fabry disease to those in age and sex matched
controls using both visual stimulation and acetazolamide
challenge by [15O]H2O and positron emission tomogra-
phy (PET) to measure rCBF. The patients were then re-ex-
amined following a 6-month double-blind placebo-
controlled trial of enzyme replacement therapy (ERT).
Functional activation by visual stimulation was chosen to
examine the vertebro-basilar diathesis of Fabry disease.
Acetazolamide, on the other hand, was hypothesized to
identify areas of decreased cerebral perfusion following
maximal cerebral vasodilation in Fabry disease compared
to controls. Such an abnormality, if present, might then
be used to assess the therapeutic efficacy of enzyme re-
placement therapy.
We define our usage of the term cerebral vasomotor reserve
as (∆CBFres) the CBF response at 20 or 30 minutes post-
acetazolamide challenge minus the resting CBF for each
subject. We define cerebral vascular reactivity as the func-
tional CBF response to a stimulus minus the resting CBF
(∆CBFreact) while the maximal response to acetazolamide
challenge provides an index of the cerebrovascular capac-
ity. The CBF response curve to acetazolamide can be con-
sidered like a high pass filter with an onset time constant
to a steady state τ1 and an offset time constant of τ2. Alter-
ation and prolongation of τ2 will correspond to prolonged
cerebral vascular response time. An important concept of a
high pass filter is that the system response is dependent on
both the resistive (R) and capacitative (C) elements.
Hence, the steady state value as well as time constants τ1
and τ2 depend on both the R and C components. There-
fore the value of ∆CBFres also depends on the RC compo-
nent of the cerebral vascular system so that if there is an
increased R component then ∆CBFres will be reduced, a
situation seen in cerebral vaso-occlusive disease. If on the
other hand the RC components are approximately equal
in the comparison groups, similar steady state values of
CBF and ∆CBFres values will be seen. The magnitude of
the steady state response by itself gives an index of the cer-
ebrovascular capacitative component (C).
Patients and Methods
Patients
The methodology for this work has been described in de-
tail [5]. Twenty-six male hemizygote patients with Fabry
disease (age range 19–48, mean age 33.7 ± 8.1 years) and
10 control subjects (age range 21–48 years, mean age 33.4
± 9.7 years) were enrolled in the study. The Institutional
Review Board of the National Institute of Neurological
Disorders and Stroke and the NIH Radiation Safety Com-
mittee approved the study and all patients and healthy
volunteers gave their written and informed consent. All
patients recruited to this study had neuropathic pain
(main inclusion criterion) no focal or global neurological
deficits and normal clotting function. Radiological evi-
dence consistent with small vessel disease was noted pri-
marily on the FLAIR MRI as hyper-intense signal areas in
10 patients. Four patients had one lesion on FLAIR imag-
ing, three patients had 3 lesions and three patients had >
3 lesions. There was no significant progression of the le-
sion burden over the 6-month trial period. No significant
radiological abnormality was found on magnetic reso-
nance angiography in the Fabry patients with no report of
dolichoectasia. One patient, randomized to the placebo
study arm, withdrew from the study for personal reasons
and three further patients (1 from the ERT group and 2
from the placebo group) declined the follow-up aceta-
zolamide challenge arm of the study at completion of the
trial. A further patient had suffered a lacunar infarct ten
years prior to commencement of the present study. The
double-blind placebo-controlled randomized trial of ERT
consisted of intravenous infusions of α galactosidase A
(Replagal™) every two weeks (Transkaryotic Therapies,
Inc., Cambridge, MA) with fourteen patients receiving
ERT and twelve placebo for six months.
PET Procedure
PET was performed with a Scanditronix PC2048-15B tom-
ograph (tranverse resolution of ~6.5 mm). A radial arterial
line was placed in all participants for measurement of the
[15O]H2O input function and arterial blood gases. Sub-
jects were aligned in the scanner with slices parallel to the
orbital-meatal line with at least one slice obtained within
the posterior fossa. The head was restrained with a ther-
moplastic facemask. Transmission scans were obtained
with a rotating 68Ge/68Ga pin source, and were used to
correct emission scans for attenuation.
Emission scans (four minutes duration) were obtained af-
ter intravenous injection of 35 mCi of [15O]H2O and werePage 2 of 10
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the brain. Each study commenced with a sham scan in or-
der to acclimatize the subject to scanning procedure
which was followed by two resting cerebral blood flow
scans during which the subject maintained eye closure.
Two scans during visual stimulation were also performed
10 minutes apart. During visual activation the subjects
were asked to focus on a black and white pattern reversal
screen. The reversal frequency was 8 Hz. This stimulus fre-
quency is known to induce the maximal change in the stri-
ate cortex blood flow [12]. The visual stimulus was
commenced ~15 seconds before radioactivity reached the
head. Following the visual activation scans, intravenous
acetazolamide was injected at a dose of 15 mg/kg body
weight and two further scans were obtained 20 and 30
minutes later.
Data Analysis
The time shift between arterial blood and brain data was
determined by aligning the scanner count rate data (sam-
pled at ~1 Hz) to the blood data with the slice count data
fitted to a one-tissue compartment two-parameter model.
The CBF images were constructed from a pixel-by-pixel
least square fit for blood flow and partition coefficient
[13,14]. The MRI T1 template was downloaded from the
Montreal Neurological Institute  [http://
www.bic.mni.mcgill.ca/] [15]. This served as a template
for spatially registering the PET data. Prior to spatial regis-
tration the MRI template and PET rCBF images were resa-
mpled to 256×256×90, 0.9375 mm isotropic voxels.
Pixel-by-pixel averaging of the replicated visual activation
PET scans was performed. Spatial registration of the PET
images and T1 MRI template was performed using SPM99
[http://www.fil.ion.ucl.ac.uk/spm/spm99.html] [16].
The analysis is divided into a comparison of the baseline
Fabry group with the control group and the comparison of
the ERT group with the placebo group. A straight compar-
ison was made between the control group and the base-
line (time zero) Fabry group visual and acetazolamide co-
registered PET data using SPM99 allowing appropriate
multiple comparisons analyses. In order to isolate a po-
tential treatment effect following ERT, a mixed statistical
model was used. This analysis of variance model divides
the total variance into fixed and random effects with the
treatment effect attributable to the fixed effect. A two-step
approach was adopted. The first allowing isolation of the
fixed effect by forming subtraction images for each patient
by subtracting the pre-trial response from the post-trial re-
sponse forming a contrast image. The second consisted of
direct comparison of the ERT and non-ERT subgroups
contrast images. In this way, the attributable treatment ef-
fects were compared for the analysis of the visual activa-
tion and acetazolamide responses on a patient-by-patient
basis. This gave for each patient a difference image repre-
senting an independent estimate of each subject's re-
sponse to visual activation and acetazolamide after ERT or
placebo. Statistical parametric maps (SPM{t}) were then
calculated on the spatially registered PET images by ob-
taining a set-level statistic of p < 0.05 after setting the voxel
threshold at p < 0.05 or less and the cluster extent at 1024
or greater. The cluster extent threshold represents ~1.0
cm3 of brain tissue. The set-level statistic represents the
statistical significance of the compared data volumes. All
the p-values given in the 'Results' section are the set-level
statistic.
In order to characterize the visual activation response fur-
ther, a specific region of interest (ROI) was used that in-
cluded Brodmann areas 17, 18 and 19 as determined from
the Talairach-Tournoux electronic brain atlas [17]. The
visual ROI was derived from T1 MRI template which was
then used to mask the SPM registered CBF images prior to
calculation of the visual CBF responses. The mean visual
cortex CBF and global CBF values were calculated on a
pixel-by-pixel basis after setting a CBF threshold value of
10.0 ml/min/100 g of tissue below which the pixels were
excluded from calculation. This CBF level represents the
lower limit of CNS tissue viability. The ROI consisted of
both gray and white matter areas associated with the visu-
al cortex and association areas.
Results
No statistical significant difference was found at baseline
between control subjects and patients for age, arterial
blood gas parameters (PaO2, PaCO2, pH) and the visual
angle subtended by the visual activation screen. This was
also true comparing the ERT and placebo groups at base-
line and after the six-month enzyme replacement therapy
trial. The global CBF post acetazolamide challenge and
mean visual ROI cerebral blood flow results are summa-
rized in Table 1 and 2.
Visual Activation Studies (Table 1)
Mean absolute CBF in the visual cortex was significantly
greater in Fabry patients during visual stimulation com-
pared to the control group (p = 0.002). The visual CBF re-
activity (∆CBFreact) following visual stimulation was
calculated in each subject by subtracting the visual cortex
resting cerebral blood flow from the mean visual activa-
tion CBF. No significant difference was found in the visual
area ∆CBFreact between patients and controls. After en-
zyme replacement therapy there was no significant change
in the mean absolute CBF response to visual stimulation
over the visual area (p = 0.184), or in ∆CBFreact compared
to placebo (p = 0.629).
Acetazolamide Challenge Studies – global CBF (Table 2)
Resting and post-acetazolamide global CBF values were
not significantly different between the control group andPage 3 of 10
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or thirty-minute time point. Following the enzyme re-
placement trial, no significant change in the global CBF
was found at the 20-minutes post-acetazolamide time
point in the ERT group compared to the placebo group,
however, the resting global CBF in the ERT group was sig-
nificantly decreased (p = 0.026). A significant reduction
(p = 0.036) in the global CBF was found 30-minutes post-
acetazolamide in the ERT group compared to the placebo
group. No difference in the global vasomotor reserve was
found between Fabry patients and controls before or fol-
lowing ERT.
Regional SPM Analysis of Visual Activation and Acetazola-
mide Challenge Studies
There was a significantly increased blood flow in the Fabry
patients during visual stimulation compared to controls
(Figure 1, p < 0.001). The increased rCBF was found pre-
dominantly in the posterior circulation area and visual
cortex but some voxels increases in rCBF were found in
the anterior circulation. No rCBF voxels were found to be
significantly greater in the control group compared to the
Fabry group (data not shown). Restriction of the rCBF
analysis to Talairach-defined visual cortex ROI showed no
significant difference in visual reactivity (∆CBFreact) be-
tween the patient and control groups.
Following acetazolamide at the 20-minute time point, the
rCBF in the control group was significantly elevated in a
more central and anterior distribution (p = 0.041), while
the distribution of the higher rCBF voxels in the Fabry
group was more posterior (data not shown, p = 0.002). At
the 30-minute time point the significantly elevated rCBF
in the control group had disappeared while the signifi-
cantly elevated rCBF in the Fabry group persisted (Figure
2, p = 0.003) indicating a prolonged cerebral vascular re-
sponse time. No difference in regional ∆CBFres between
the Fabry and control groups was found indicating nor-
mal regional cerebral vascular reserve in Fabry disease.
ERT resulted in a significantly lower absolute rCBF during
visual stimulation in the treatment group compared to the
placebo (Figure 3, p < 0.001) while no significantly de-
creased areas of rCBF were found in the placebo group. A
Table 1: Summary of mean visual area CBF and reactivity in Fabry disease compared to controls together with the mean visual area 
resting and post stimulation CBF changes in the ERT Fabry and placebo groups following the double-blind, placebo-controlled rand-
omized trial. All values are means ± standard deviation.
Cerebral Blood Flow [ml/min/100 g tissue] Fabry Patients n = 26 Control Subjects n = 10 P value
Rest 25.7 ± 3.8 22.8 ± 2.9 0.019
Visual Activation 29.43 ± 3.44 25.78 ± 2.45 0.002
Change with visual activation 3.74 ± 2.91 3.0 ± 2.88 0.498





Change in resting rCBF -2.3 ± 3.7 1.1 ± 4.2 0.050
Change in rCBF during visual activation -1.75 ± 2.6 0.61 ± 5.08 0.184
Mean Visual Area Reactivity 0.51 ± 3.41 -0.47 ± 5.84 0.629
Table 2: Summary of global resting and post-acetazolamide CBF in Fabry disease compared to controls together with the mean resting 
and post-acetazolamide global CBF changes in the ERT Fabry and placebo groups following the double-blind, placebo-controlled rand-
omized trial. All values are means ± standard deviation.
Global Cerebral Blood Flow [ml/min/100 g tissue] Fabry Patients Control Subjects P value
Rest 42.0 ± 4.9, n = 26 39.2 ± 4.8, n = 10 0.136
Post-acetazolamide 20 minute time point 57.5 ± 8.9, n = 26 57.9 ± 7.9, n = 9 0.969
Post-acetazolamide 30 minute time point 56.9 ± 7.9, n = 26 54.2 ± 8.6, n = 10 0.406
Cerebral Blood Flow change Post-ERT or Placebo Enzyme Replacement Group Placebo Group P value
Resting Cerebral Blood Flow -3.5 ± 4.6, n = 14 1.3 ± 5.1, n = 11 0.026
Post-acetazolamide 20 minute time point -3.9 ± 7.9, n = 13 0.5 ± 10.8, n = 9 0.314
Post-acetazolamide 30 minutes time point -7.0 ± 5.5, n = 13 1.1 ± 9.2, n = 9 0.036Page 4 of 10
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rCBF SPM{t} map of significantly increased blood flow in the Fabry group (n = 26) compared to the control group (n = 10) dur-
ing visual stimulation. No significant rCBF elevation was found in the control group compared to Fabry patients at the same
set-level of inference (results not shown).Page 5 of 10
(page number not for citation purposes)
BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/4Figure 2
Acetazolamide challenge rCBF SPM{t} map of significantly increased blood flow in the Fabry group (n = 26) compared to nor-
mal controls (n = 10). The rCBF at thirty minutes post-infusion of acetazolamide was significantly greater in Fabry patients in
many brain regions, with a posterior predominance. No significant rCBF elevation at the same set-level of inference was found
in the control group compared to Fabry patients (results not shown).Page 6 of 10
(page number not for citation purposes)
BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/4Figure 3
SPM{t} map of significantly lower rCBF in the ERT treatment group (n = 14) during visual stimulation compared to the placebo
group (n = 11) in many regions throughout the brain.Page 7 of 10
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SPM{t} map of significantly lower rCBF 30-minute following acetazolamide challenge in the ERT group (n = 13) compared to
the placebo group (n = 9).Page 8 of 10
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restricted to the visual cortex (p < 0.001) with no areas of
significantly decreased rCBF in the placebo group. ERT led
to decreased rCBF after acetazolamide infusion at both
time points (time = 20 minutes, p < 0.001, time = 30 min-
utes, p = 0.004, Figure 4). No significant decrease in rCBF
was found at a comparable cluster extent and voxel thresh-
old in the placebo group.
Discussion
Our data indicate the presence of an abnormal functional
response to visual stimulation both in global and regional
CBF analysis in Fabry disease. This however was not due
to an alteration in vascular reactivity. Previously, we dem-
onstrated that the resting rCBF in Fabry disease is elevated
compared to controls particularly in the posterior circula-
tion [5]. In view of the normal visual area reactivity in Fab-
ry disease, these findings indicate that the Fabry group
response to visual activation is largely explained by the el-
evated resting rCBF. However, the more generalized cere-
brovascular response noted in both the carotid and
vertebro-basilar circulation suggests stimulus spread in
Fabry disease, possibly due to a decreased response
threshold in non-visual cortex vasculature. Following
ERT, this resting rCBF abnormality was reversed [5].
The cerebral visual stimulation paradigm used in the cur-
rent study is known to induce maximal cerebral blood
flow [12] and is therefore a useful stimulus for the study
of neuro-vascular coupling. Visual stimulation was cho-
sen in particular because of the known predilection of the
cerebrovascular abnormalities in Fabry disease for the
posterior circulation [7,10]. The lack of an increase or de-
crease in visual rCBF reactivity in Fabry disease suggests
normal neuro-vascular coupling mechanism [18,19].
Acetazolamide-induced maximal cerebral vasodilatory re-
sponse is often used to assess cerebrovascular reserve [20].
The greatest difference between our patients and controls
occurred at the 30-minute time point rather than at the
20-minute time point of the acetazolamide challenge.
This finding is consistent with a prolongation of the cere-
bral vascular response time in the Fabry disease. ERT sig-
nificantly decreased the prolonged cerebral vascular
response time. The vasodilator effect of acetazolamide on
the cerebral vasculature has been characterized by both
PET and transcranial Doppler (TCD) studies [21,22]. At a
dose of 15 mg/kg the effect of acetazolamide is thought to
be supramaximal with maximal cerebral vasodilation in-
duced within about 20 minutes. By TCD a maximal dose-
response was found to occur with an acetazolamide infu-
sion of between 15 and 18 mg/kg with maximal vasoreac-
tivity occurring between 10 and 30 minutes post
acetazolamide [21]. Using [15O]H2O and PET, a further
study of rCBF following 1 g of acetazolamide demonstrat-
ed the peak response to occur at 10 minutes while the pla-
teau phase occurred during the twenty to thirty minute
time period post acetazolamide [22]. The measurements
in the current study obtained at twenty and thirty minutes
post acetazolamide injection therefore, probably corre-
sponds to the plateau phase of reported acetazolamide re-
sponses.
The CBF response to supra-maximal acetazolamide chal-
lenge consists of a phase of increasing CBF followed by a
plateau phase with a terminal recovery phase. This can be
considered in terms of cerebrovascular resistance and ca-
pacity, analogous to a high pass filter where high frequen-
cy components of the system response are removed. The
importance of this analogy is that the plateau response is
dependent on both the system's resistive and capacitative
components. In the present study it was seen that the vas-
omotor reserve in Fabry disease was within normal limits
despite the elevated resting rCBF. The cerebrovascular ca-
pacity in Fabry disease was also within normal limits, sug-
gesting absence of clinically significant vaso-occlusive
disease in the cohort of Fabry patients examined. This
finding is supported by the absence of abnormalities on
magnetic resonance angiography in the same group. Re-
duced ∆CBFres would be expected when the resistive com-
ponent is increased reducing the amplitude of the
acetazolamide induced plateau response.
The hyperemic cerebrovascular response to hypercapnia
or acetazolamide is not inhibited by nitric oxide synthase
inhibitors such as NG-monomethyl-L-arginine (L-NM-
MA) suggesting that NO does not mediate vasoreactivity
[23,24]. The mechanism of acetazolamide vasodilation,
beyond smooth muscle intracellular and extracellular aci-
dosis due carbonic anhydrase inhibition, is unclear. Ab-
normalities of the peripheral vasculature responses to
acetylcholine have been previously described in Fabry dis-
ease together with nitric oxide pathway dysregulation
[5,9] suggesting participation of non-NO regulation of
vascular tone. A similar vascular hyper-responsiveness has
been noted in caveolin-1 knock-out mice [25,26] raising
the possibility that the accumulation of Gb3 results in
over-activity of uncoupled endothelial nitric oxide syn-
thase within endothelial cell caveolae generating superox-
ide and other reactive oxygen species [27]. The latter may
have a vasodilatatory effect [28]. Predominance of vascu-
lar abnormalities in the vertebro-basilar system in Fabry
disease suggests fundamental biologic differences be-
tween the anterior and the posterior circulation. Such dif-
ference might, for example, result from the neural crest
origin of pericytes and vascular smooth muscle in the an-
terior circulation as opposed to paraxial mesoderm in the
vertebro-basilar or posterior circulation [29].Page 9 of 10
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The current study indicates that ERT normalized aceta-
zolamide-induced prolonged cerebral vascular response
time in Fabry disease. This finding suggests that the under-
lying abnormality is present at the luminal side of the
blood-brain barrier (BBB) complex and is due to an ab-
normality of the cerebral vessels since it is unlikely that α-
galactosidase A crosses the BBB to any appreciable extent.
Further, the treatment effect appeared to be uniform
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